Carcinoma News and Research

RSS

Carcinoma is cancer that begins in the skin or in tissues that line or cover internal organs.

Combined GLP-1 and GLP-2 treatment appears safe but does not beat placebo for obesity

In a 12-week randomized phase IIa trial in adults with obesity, the dual GLP-1/GLP-2 receptor agonist dapiglutide was well tolerated but did not achieve statistically significant weight loss compared with placebo at 4 mg or 6 mg doses. Although the higher dose showed modest within-group weight reduction and improved HbA1c, unexpectedly substantial placebo-associated weight loss limited the observed treatment effect.

24 Feb 2026

How GLP-1 drugs affect the body beyond weight loss and glucose control

This review evaluates the safety profile of glucagon-like peptide-1 receptor agonists and related incretin therapies used for obesity and type 2 diabetes. It highlights common gastrointestinal effects, rare but debated risks, and areas where further long-term safety data are still needed.

18 Feb 2026

Polyploidy-induced senescence may influence aging and cancer risk

A new editorial was published in Volume 18 of Aging-US on February 8, 2026, titled "Polyploidy-induced senescence: Linking development, differentiation, repair, and (possibly) cancer?"

18 Feb 2026

Researchers develop new score to predict the risk of liver cancer

Researchers led by Xian-Yang Qin at the RIKEN Center for Integrative Medical Sciences (IMS) in Japan have developed a score that predicts the risk of liver cancer.

17 Feb 2026

Cornell study finds existing drug could boost liver cancer immunotherapy

Immunotherapy – which activates the body's own immune system to kill cancer cells – has not worked well against a rare and fatal liver cancer, but a new Cornell University study finds an existing FDA-approved drug may allow the immunotherapy to fight the cancer as intended, opening the door to a potential treatment.

17 Feb 2026

Nanovaccine design boosts immune attack on HPV tumors

Throughout the past decade, Northwestern University scientists have uncovered a striking principle of vaccine design: Performance depends not only on vaccine components but also on vaccine structure.

11 Feb 2026

Review links betel nut addiction to cancer, heart disease, and metabolic risks

This review examines the epidemiology, health risks, neurobiological mechanisms, and emerging treatments related to betel nut addiction worldwide. It highlights strong links with oral cancer, cardiometabolic disease, and addiction pathways while noting limited established therapies and the need for coordinated public health strategies.

11 Feb 2026

University of Missouri launches first on-campus radiopharmaceutical clinical trial

In a major leap for cancer care at the University of Missouri, the School of Medicine and MU Health Care have launched their first clinical trial using a leading-edge therapy manufactured on campus at the university's research reactor.

10 Feb 2026

Genetic ancestry influences tumor biology and survival in head and neck cancers

Genetic ancestry plays a key role in determining the behavior of head and neck tumors and may help explain why African-American patients survive for half as long as their counterparts of European ancestry, according to a new review study led by researchers from the University of Maryland School of Medicine's (UMSOM) Institute for Genome Sciences (IGS) and the University of Maryland Greenebaum Comprehensive Cancer Center (UMGCCC).

31 Jan 2026

Characteristic features of bone marrow metastasis from non-hematolymphoid malignancies

Bone marrow metastasis (BMM) from non-hematolymphoid malignancies with resultant cytopenia(s) can mimic primary hematolymphoid disorders. This study aimed to investigate the clinical and pathological characteristics of BMM from non-hematopoietic tumors.

30 Jan 2026

Prognostic nutritional index proposed as prognostic marker in hepatocellular carcinoma

The prognostic nutritional index (PNI), calculated from serum albumin and lymphocyte count, reflects a patient's immune-nutritional status and has been proposed as a prognostic marker in hepatocellular carcinoma (HCC).

27 Jan 2026

Diagnostic prognostic and therapeutic relevance of PIVKA-II in hepatocellular carcinoma

Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality worldwide, particularly in regions with high hepatitis B virus prevalence.

24 Jan 2026

Unraveling liver injury mechanisms in familial hypobetalipoproteinemia

Familial Hypobetalipoproteinemia (FHBL), caused by variants in the apolipoprotein B (APOB) gene, is a rare autosomal co-dominant monogenic disorder characterized by lifelong low plasma levels of total cholesterol, low-density lipoprotein cholesterol (LDL-C), and APOB.

24 Jan 2026

Dual-responsive nanodelivery system enhances immunotherapy efficacy in metastatic bladder cancer

Metastatic urothelial carcinoma has a poor prognosis: ~50% of muscle-invasive bladder cancer progresses to metastasis, and the 5-year survival for advanced/metastatic disease is <10%.

24 Jan 2026

Cigarette compound exposure drives sorafenib resistance in hepatocellular carcinoma

A research team led by Professor Yuan Li at Nanjing Medical University published a research paper entitled "A Cigarette Compound-Induced Tumor Microenvironment Promotes Sorafenib Resistance in Hepatocellular Carcinoma via the 14-3-3η-Modified Tumor-Associated Proteome" in the Chinese Medical Journal.

23 Jan 2026

Expert guidance on fecal microbiota transplantation in liver disease

The gut microbiota plays a crucial role in maintaining host health and liver function. Fecal microbiota transplantation (FMT), an emerging therapeutic modality, has demonstrated promising potential in the treatment of chronic liver diseases.

22 Jan 2026

Myosteatosis: An emerging predictor of outcomes in chronic liver disease

Myosteatosis, the pathological infiltration of fat into skeletal muscle, is increasingly recognized as a key predictor of poor clinical outcomes across a spectrum of liver diseases.

22 Jan 2026

NuSHs can be a promising therapeutic strategy for preventing MASH-related hepatocellular carcinoma

Metabolic dysfunction-associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction-associated steatohepatitis (MASH), represent the most common chronic liver diseases in Western populations, driven largely by obesity and insulin resistance.

21 Jan 2026

Mitotane’s role in the management of adrenocortical carcinoma

Adrenocortical carcinoma (ACC) is a rare but aggressive malignancy with high postoperative recurrence rates and poor prognosis. Mitotane remains the only approved agent for ACC, exerting antitumor effects by disrupting mitochondrial integrity, inhibiting steroidogenic enzymes, and interfering with cholesterol metabolism.

21 Jan 2026

A dual-action approach to preventing hepatocellular carcinoma

Hepatocellular carcinoma is one of the leading causes of cancer-related death worldwide, largely due to its high rate of recurrence after surgery. Even after complete tumor removal, microscopic residual disease and early dissemination frequently lead to relapse within the first two years.

21 Jan 2026

Carcinoma News and Research

Further Reading

Combined GLP-1 and GLP-2 treatment appears safe but does not beat placebo for obesity

How GLP-1 drugs affect the body beyond weight loss and glucose control

Polyploidy-induced senescence may influence aging and cancer risk

Researchers develop new score to predict the risk of liver cancer

Cornell study finds existing drug could boost liver cancer immunotherapy

Nanovaccine design boosts immune attack on HPV tumors

Review links betel nut addiction to cancer, heart disease, and metabolic risks

University of Missouri launches first on-campus radiopharmaceutical clinical trial

Genetic ancestry influences tumor biology and survival in head and neck cancers

Characteristic features of bone marrow metastasis from non-hematolymphoid malignancies

Prognostic nutritional index proposed as prognostic marker in hepatocellular carcinoma

Diagnostic prognostic and therapeutic relevance of PIVKA-II in hepatocellular carcinoma

Unraveling liver injury mechanisms in familial hypobetalipoproteinemia

Dual-responsive nanodelivery system enhances immunotherapy efficacy in metastatic bladder cancer

Cigarette compound exposure drives sorafenib resistance in hepatocellular carcinoma

Expert guidance on fecal microbiota transplantation in liver disease

Myosteatosis: An emerging predictor of outcomes in chronic liver disease

NuSHs can be a promising therapeutic strategy for preventing MASH-related hepatocellular carcinoma

Mitotane’s role in the management of adrenocortical carcinoma

A dual-action approach to preventing hepatocellular carcinoma

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News